Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Capricor Therapeutics Inc (CAPR)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Capricor Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.900 -0.280    -3.42%
01/08 - Closed. Currency in USD
After Hours
7.870
-0.030
-0.380%
23:43:37 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 1,790,525
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 7.720 - 8.280
Capricor Therapeutics 7.900 -0.280 -3.42%

Capricor Therapeutics Inc Company Profile

 
Get an in-depth profile of Capricor Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

160

Equity Type

ORD

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.

Contact Information

Address 10865 Road to the Cure Suite 150
San Diego, 92121
United States
Phone 858 727 1755
Fax -

Top Executives

Name Age Since Title
Barry J. Byrne - - Member of Scientific Advisory Board
Thomas Voit - - Member of Scientific Advisory Board
Frank Isaac Litvack 69 2012 Executive Chairman of the Board
Linda Marbán 62 2010 Co-Founder, President, CEO & Director
George W. Dunbar 78 2013 Independent Director
David Brian Musket 67 2013 Independent Director
Francesco Muntoni - - Member of Scientific Advisory Board
Michelle Eagle - - Member of Scientific Advisory Board
Craig McDonald - - Member of Scientific Advisory Board
Pat Furlong - - Member of Scientific Advisory Board
Eugenio Mercuri - - Member of Scientific Advisory Board
Karimah Es Sabar 67 2021 Independent Director
Michael Taylor - 2018 Member of Scientific Advisory Board
Oscar Henry Mayer - - Member of Scientific Advisory Board
Philip J. Gotwals 62 2023 Independent Director
Paul Gisbert Auwaerter 63 2023 Independent Director
Michael Kelliher 48 2023 Independent Director
Timothy R. Franson 73 2023 Member of the Scientific Advisory Board
Suzanne Hendrix - 2023 Member of Scientific Advisory Board
Chet Villa - 2023 Member of the Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CAPR Comments

Write your thoughts about Capricor Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email